RXRX RECURSION PHARMACEUTICALS, INC.
Nasdaq · SEC CIK 1601830 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $8.93M 36 sales by 5 insiders
- Filings on record
- 457 since 2021-07-06, latest 2026-09-16 17:52
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Borgeson Blake | Dir | — | $4.10M |
| Gibson Christopher | Dir | — | $3.84M |
| Khan Najat | Chief R, D Commercial Off, Dir | — | $806.7K |
| Taylor Ben R | CFO | — | $157.7K |
| Bumpus Namandje | Dir | — | $28.1K |
| Michor Franziska | Dir | — | — |
| Hallett David | CSO | — | — |
| Dar Zavain | Dir | — | — |
| Li Dean Y | Dir | — | — |
| Sun Elaine D | Dir | — | — |
Transactions 743
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2023-02-14 | 2023-02-13 | RXRX | Mubadala Investment Co PJSC | 10% | P - Purchase | $7.97 | +32.5K | 12.40M | +0.3% | +$258.8K |
| I | 2023-02-13 | 2023-02-10 | RXRX | Mamoura Diversified Global Holding PJSC | 10% | P - Purchase | $7.98 | +11.0K | 12.37M | +0.1% | +$87.8K |
| 2023-02-09 | 2023-02-07 | RXRX | Borgeson Blake | Dir | S - Sale | $8.81 | -8,885 | 7.60M | -0.1% | -$78.3K | |
| DM | 2023-02-03 | 2023-02-01 | RXRX | Secora Michael | CFO | A - Grant | $0.00 | +210.2K | 790.5K | +36% | $0 |
| D | 2023-02-03 | 2023-02-01 | RXRX | Secora Michael | CFO | F - Tax | $8.55 | -2,669 | 795.6K | -0.3% | -$22.8K |
| DM | 2023-02-03 | 2023-02-01 | RXRX | Larson Tina Marriott | Pres, COO | A - Grant | $0.00 | +226.8K | 422.8K | +116% | $0 |
| D | 2023-02-03 | 2023-02-01 | RXRX | Larson Tina Marriott | Pres, COO | F - Tax | $8.55 | -3,093 | 429.4K | -0.7% | -$26.4K |
| D | 2023-02-03 | 2023-02-02 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +18.5K | 960.8K | +2% | $0 |
| D | 2023-02-03 | 2023-02-01 | RXRX | Gibson Christopher | CEO, Dir | F - Tax | $8.55 | -1,382 | 942.3K | -0.1% | -$11.8K |
| DM | 2023-02-03 | 2023-02-01 | RXRX | Gibson Christopher | CEO, Dir | A - Grant | $0.00 | +417.9K | 932.6K | +81% | $0 |
| DMI | 2023-02-03 | 2023-02-02 | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $9.21 | -2,500 | 0 | -100% | -$23.0K |
| DMI | 2023-02-03 | 2023-02-02 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +2,500 | 1,000 | New | $0 |
| D | 2023-02-03 | 2023-02-02 | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $9.22 | -18.5K | 942.3K | -2% | -$170.6K |
| DM | 2023-02-03 | 2023-02-01 | RXRX | Virani Shafique | Chief Business Off | A - Grant | $0.00 | +117.1K | 192.8K | +155% | $0 |
| D | 2023-02-03 | 2023-02-01 | RXRX | Virani Shafique | Chief Business Off | F - Tax | $8.55 | -2,994 | 189.8K | -2% | -$25.6K |
| I | 2023-02-02 | 2023-02-01 | RXRX | Mubadala Investment Co PJSC | 10% | P - Purchase | $7.97 | +600 | 12.35M | +0.0% | +$4,782 |
| D | 2023-01-27 | 2023-01-26 | RXRX | Larson Tina Marriott | Pres, COO | S - Sale+OE | $8.07 | -8,000 | 203.7K | -4% | -$64.6K |
| D | 2023-01-27 | 2023-01-26 | RXRX | Larson Tina Marriott | Pres, COO | M - OptEx | $1.06 | +8,000 | 211.7K | +4% | +$8,480 |
| I | 2023-01-27 | 2023-01-26 | RXRX | Mamoura Diversified Global Holding PJSC | 10% | P - Purchase | $7.99 | +7,886 | 12.35M | +0.1% | +$63.0K |
| I | 2023-01-26 | 2023-01-25 | RXRX | Mamoura Diversified Global Holding PJSC | 10% | P - Purchase | $7.88 | +24.5K | 12.35M | +0.2% | +$193.3K |
| 2023-01-26 | 2023-01-24 | RXRX | Borgeson Blake | Dir | S - Sale | $8.71 | -8,885 | 7.61M | -0.1% | -$77.4K | |
| D | 2023-01-19 | 2023-01-17 | RXRX | Virani Shafique | Chief Business Off | S - Sale+OE | $9.16 | -10.0K | 73.2K | -12% | -$91.6K |
| D | 2023-01-19 | 2023-01-17 | RXRX | Virani Shafique | Chief Business Off | M - OptEx | $2.22 | +5,000 | 83.2K | +6% | +$11.1K |
| MI | 2023-01-13 | 2022-12-23+ | RXRX | Mamoura Diversified Global Holding PJSC | 10% | P - Purchase | $7.50 | +1.03M | 11.94M | +9% | +$7.73M |
| 2023-01-12 | 2023-01-10 | RXRX | Borgeson Blake | Dir | S - Sale | $7.69 | -8,885 | 7.62M | -0.1% | -$68.3K | |
| DM | 2023-01-06 | 2022-04-25+ | RXRX | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -57.0K | 570.8K | -9% | $0 |
| D | 2023-01-06 | 2023-01-05 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +18.5K | 544.3K | +4% | $0 |
| D | 2023-01-06 | 2023-01-05 | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $7.39 | -18.5K | 525.8K | -3% | -$136.7K |
| DMI | 2023-01-06 | 2023-01-05 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +2,500 | 1,000 | New | $0 |
| DMI | 2023-01-06 | 2023-01-05 | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $7.38 | -2,500 | 0 | -100% | -$18.5K |
| 2023-01-05 | 2023-01-03 | RXRX | Li Dean Y | Dir | A - Grant | $0.00 | +1,573 | 621.7K | +0.3% | $0 | |
| 2023-01-05 | 2023-01-03 | RXRX | CHAVEZ R. MARTIN | Dir | A - Grant | $0.00 | +2,483 | 35.7K | +7% | $0 | |
| 2023-01-05 | 2023-01-03 | RXRX | Borgeson Blake | Dir | A - Grant | $0.00 | +1,325 | 7.63M | +0.0% | $0 | |
| 2023-01-05 | 2023-01-03 | RXRX | Burrell Terry-Ann | Dir | A - Grant | $0.00 | +1,821 | 159.2K | +1% | $0 | |
| 2023-01-05 | 2023-01-03 | RXRX | Bogue Zachary | Dir, 10% | A - Grant | $0.00 | +1,407 | 6,396 | +28% | $0 | |
| D | 2022-12-30 | 2022-12-29 | RXRX | Larson Tina Marriott | Pres, COO | S - Sale+OE | $7.70 | -8,000 | 203.7K | -4% | -$61.6K |
| D | 2022-12-30 | 2022-12-29 | RXRX | Larson Tina Marriott | Pres, COO | M - OptEx | $1.06 | +8,000 | 211.7K | +4% | +$8,480 |
| 2022-12-29 | 2022-12-27 | RXRX | Borgeson Blake | Dir | S - Sale | $7.25 | -8,885 | 7.63M | -0.1% | -$64.4K | |
| D | 2022-12-19 | 2022-12-15 | RXRX | Virani Shafique | Chief Business Off | S - Sale+OE | $8.85 | -10.0K | 78.2K | -11% | -$88.5K |
| D | 2022-12-19 | 2022-12-15 | RXRX | Virani Shafique | Chief Business Off | M - OptEx | $2.22 | +5,000 | 88.2K | +6% | +$11.1K |
| 2022-12-15 | 2022-12-13 | RXRX | Borgeson Blake | Dir | S - Sale | $8.96 | -8,885 | 7.64M | -0.1% | -$79.6K | |
| D | 2022-12-02 | 2022-12-01 | RXRX | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +31.2K | 601.5K | +5% | +$77.5K |
| DM | 2022-12-02 | 2022-12-01 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $9.02 | -37.2K | 582.8K | -6% | -$335.8K |
| D | 2022-12-02 | 2022-12-01 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +18.5K | 601.3K | +3% | $0 |
| DMI | 2022-12-02 | 2022-12-01 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +2,500 | 500 | New | $0 |
| DMI | 2022-12-02 | 2022-12-01 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $9.28 | -2,500 | 0 | -100% | -$23.2K |
| 2022-12-01 | 2022-11-29 | RXRX | Borgeson Blake | Dir | S - Sale | $8.75 | -8,885 | 7.65M | -0.1% | -$77.7K | |
| 2022-11-18 | 2022-11-16 | RXRX | Borgeson Blake | Dir | S - Sale | $11.12 | -17.8K | 7.65M | -0.2% | -$197.6K | |
| 2022-11-17 | 2022-11-15 | RXRX | Gibson Christopher | CEO, Dir | F - Tax | $11.86 | -5,751 | 570.3K | -1.0% | -$68.2K | |
| 2022-11-17 | 2022-11-15 | RXRX | Secora Michael | CFO | F - Tax | $11.86 | -1,065 | 586.6K | -0.2% | -$12.6K | |
| D | 2022-11-17 | 2022-11-15 | RXRX | Larson Tina Marriott | Pres, COO | F - Tax | $11.86 | -1,453 | 203.7K | -0.7% | -$17.2K |
| D | 2022-11-17 | 2022-11-17 | RXRX | Larson Tina Marriott | Pres, COO | M - OptEx | $1.06 | +16.0K | 219.7K | +8% | +$17.0K |
| D | 2022-11-17 | 2022-11-17 | RXRX | Larson Tina Marriott | Pres, COO | S - Sale+OE | $10.96 | -16.0K | 203.7K | -7% | -$175.4K |
| D | 2022-11-17 | 2022-11-15 | RXRX | Virani Shafique | Chief Business Off | F - Tax | $11.86 | -613 | 88.2K | -0.7% | -$7,270 |
| D | 2022-11-17 | 2022-11-15 | RXRX | Virani Shafique | Chief Business Off | M - OptEx | $2.22 | +5,000 | 93.2K | +6% | +$11.1K |
| DM | 2022-11-17 | 2022-11-15 | RXRX | Virani Shafique | Chief Business Off | S - Sale+OE | $12.31 | -10.0K | 83.2K | -11% | -$123.1K |
| DMI | 2022-11-04 | 2022-11-03 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $10.10 | -2,500 | 0 | -100% | -$25.3K |
| DMI | 2022-11-04 | 2022-11-03 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +2,500 | 1,000 | New | $0 |
| DM | 2022-11-04 | 2022-11-03 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $10.00 | -36.7K | 576.0K | -6% | -$367.0K |
| D | 2022-11-04 | 2022-11-03 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +18.5K | 594.5K | +3% | $0 |
| D | 2022-11-04 | 2022-11-03 | RXRX | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +31.2K | 594.2K | +6% | +$77.5K |
| I | 2022-10-31 | 2022-10-27 | RXRX | Mubadala Investment Co PJSC | 10% | A - Grant | $9.80 | +2.55M | 11.29M | +29% | +$25.00M |
| D | 2022-10-28 | 2022-10-27 | RXRX | Larson Tina Marriott | Pres, COO | S - Sale+OE | $10.72 | -16.0K | 205.1K | -7% | -$171.5K |
| D | 2022-10-28 | 2022-10-27 | RXRX | Larson Tina Marriott | Pres, COO | M - OptEx | $1.06 | +16.0K | 221.1K | +8% | +$17.0K |
| D | 2022-10-18 | 2022-10-14 | RXRX | Virani Shafique | Chief Business Off | M - OptEx | $2.22 | +5,000 | 98.8K | +5% | +$11.1K |
| DM | 2022-10-18 | 2022-10-14 | RXRX | Virani Shafique | Chief Business Off | S - Sale+OE | $10.92 | -10.0K | 88.8K | -10% | -$109.2K |
| D | 2022-10-07 | 2022-10-06 | RXRX | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +31.2K | 580.5K | +6% | +$77.5K |
| DMI | 2022-10-07 | 2022-10-06 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $11.64 | -2,500 | 0 | -100% | -$29.1K |
| DMI | 2022-10-07 | 2022-10-06 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +2,500 | 500 | New | $0 |
| DM | 2022-10-07 | 2022-10-06 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $11.58 | -36.1K | 563.0K | -6% | -$417.4K |
| D | 2022-10-07 | 2022-10-06 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +18.5K | 581.5K | +3% | $0 |
| 2022-10-05 | 2022-10-03 | RXRX | Bogue Zachary | Dir, 10% | A - Grant | $0.00 | +977 | 4,989 | +24% | $0 | |
| 2022-10-05 | 2022-10-03 | RXRX | Burrell Terry-Ann | Dir | A - Grant | $0.00 | +1,265 | 157.4K | +0.8% | $0 | |
| 2022-10-05 | 2022-10-03 | RXRX | Li Dean Y | Dir | A - Grant | $0.00 | +1,092 | 620.1K | +0.2% | $0 | |
| 2022-10-05 | 2022-10-03 | RXRX | CHAVEZ R. MARTIN | Dir | A - Grant | $0.00 | +1,725 | 33.2K | +5% | $0 | |
| 2022-10-05 | 2022-10-03 | RXRX | Dir | A - Grant | $0.00 | +920 | 7.67M | +0.0% | $0 | ||
| D | 2022-10-03 | 2022-09-29 | RXRX | Larson Tina Marriott | Pres, COO | M - OptEx | $1.06 | +16.0K | 221.1K | +8% | +$17.0K |
| DM | 2022-10-03 | 2022-09-29 | RXRX | Larson Tina Marriott | Pres, COO | S - Sale+OE | $10.86 | -16.0K | 205.1K | -7% | -$173.8K |
| DM | 2022-09-16 | 2022-09-15 | RXRX | Virani Shafique | Chief Business Off | S - Sale+OE | $13.37 | -10.0K | 94.2K | -10% | -$133.7K |
| D | 2022-09-16 | 2022-09-15 | RXRX | Virani Shafique | Chief Business Off | M - OptEx | $2.22 | +5,000 | 103.8K | +5% | +$11.1K |
| DM | 2022-09-02 | 2022-09-01 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $10.34 | -36.6K | 549.3K | -6% | -$378.0K |
| D | 2022-09-02 | 2022-09-01 | RXRX | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +31.2K | 567.3K | +6% | +$77.5K |
| DMI | 2022-09-02 | 2022-09-01 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $10.50 | -2,500 | 0 | -100% | -$26.2K |
| DMI | 2022-09-02 | 2022-09-01 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +2,500 | 1,000 | New | $0 |
| D | 2022-09-02 | 2022-09-01 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +18.5K | 567.8K | +3% | $0 |
| 2022-08-17 | 2022-08-15 | RXRX | Secora Michael | CFO | F - Tax | $12.96 | -1,065 | 587.6K | -0.2% | -$13.8K | |
| D | 2022-08-17 | 2022-08-15 | RXRX | Larson Tina Marriott | Pres, COO | F - Tax | $12.96 | -1,453 | 205.1K | -0.7% | -$18.8K |
| D | 2022-08-17 | 2022-08-16 | RXRX | Larson Tina Marriott | Pres, COO | M - OptEx | $1.06 | +16.0K | 221.1K | +8% | +$17.0K |
| D | 2022-08-17 | 2022-08-16 | RXRX | Larson Tina Marriott | Pres, COO | S - Sale+OE | $12.60 | -16.0K | 295.1K | -5% | -$201.6K |
| 2022-08-17 | 2022-08-15 | RXRX | Gibson Christopher | CEO, Dir | F - Tax | $12.96 | -5,751 | 536.1K | -1% | -$74.5K | |
| D | 2022-08-17 | 2022-08-15 | RXRX | Virani Shafique | Chief Business Off | F - Tax | $12.96 | -613 | 103.8K | -0.6% | -$7,944 |
| D | 2022-08-17 | 2022-08-16 | RXRX | Virani Shafique | Chief Business Off | M - OptEx | $2.22 | +25.0K | 128.8K | +24% | +$55.5K |
| D | 2022-08-17 | 2022-08-16 | RXRX | Virani Shafique | Chief Business Off | S - Sale+OE | $12.61 | -30.0K | 98.8K | -23% | -$378.3K |
| DMI | 2022-08-05 | 2022-08-04 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +2,500 | 500 | New | $0 |
| DMI | 2022-08-05 | 2022-08-04 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $9.45 | -2,500 | 0 | -100% | -$23.6K |
| DM | 2022-08-05 | 2022-08-04 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $9.49 | -36.8K | 541.8K | -6% | -$349.5K |
| D | 2022-08-05 | 2022-08-04 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +18.5K | 560.3K | +3% | $0 |
| D | 2022-08-05 | 2022-08-04 | RXRX | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +31.2K | 560.2K | +6% | +$77.5K |
| 2022-07-12 | 2022-07-08 | RXRX | Dar Zavain | Dir | J - Other | $0.00 | +2,420 | 20.6K | +13% | $0 | |
| D | 2022-07-08 | 2022-07-07 | RXRX | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +31.2K | 547.5K | +6% | +$77.5K |
Purchase Sale Sale after option exercise All abbreviations